• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 18.60
  • VXN 23.66
  • VXO 18.16
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
VIVO (Meridian Bioscience Inc.)
Last Trade 16.78 Dividend/Share 0.5 PE Ratio 22.68
Date 12:16:14 PM Dividend Yield 2.985 Return on Assets 9.52
Change -0.1 ExDividend Date 2018-11-16 Return on Capital null
Bid 0 Latest EPS 0.56 Price/Sale 4.410
Ask 0 LatestEPS Date 2018-09-30 Price to Book 4.05
Volume 2987 EPS ttm 0.740 Institutional % 134.6
Avg Volume 0.34M Shares Outstanding 42.46M Insider % 3.7
Open 16.88 Float 40.91M Short Ratio null
Prev Close 16.88 Return On Equity 13.83 5 Year Change % -0.214
High 17.5 Consensus EPS 0.16 2 Year Change % 0.072
Low 16.73 No. of Estimate 3.000 1 Year Change % 0.139
52 Week High 19.84 EPS Surprise $ null YTD Change % 0.002
52 Week Low 13.527 EPS Surprise Percent 25 6 Month Change % 0.091
52 Week Change 13.026 EBITDA 0M 3 Month Change % 0.121
50 Day MA 17.64943 Revenue 0M 1 Month Change % -0.034
200 Day MA Gross Profit 0M 5 Day Change % 0.062
Market Cap 716.78M Cash 0M 30 Day Change % -0.109
Beta 0.498634 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. Its diagnostic test kits utilize immunodiagnostic technologies, which test samples of blood, urine, stool, and other body fluids or tissues for the presence of antigens and antibodies of specific infectious diseases. The immunodiagnostic technologies include enzyme immunoassay, immunofluorescence, particle agglutination/aggregation, immunodiffusion, complement fixation, and chemical stains. The company also provides transport media that store and preserve specimen samples from patient collection to laboratory testing. In addition, Meridian Bioscience manufactures and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. Further, it involves in the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian Bioscience markets its diagnostic test kits through direct sales force and independent distributors to reference laboratories and hospitals primarily in the United States, Canada, Belgium, France, Holland, Italy, Africa, and the Middle East. The company was founded in 1976 and is based in Cincinnati, Ohio.